Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Multiple Myeloma 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Burkitt Lymphoma 9Lymphoma, Mantle-Cell 4Breast Neoplasms 4Leukemia, Biphenotypic, Acute 3Hodgkin Disease 3Vomiting 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Plasmacytoma 2Ovarian Neoplasms 2Neoplasms, Plasma Cell 2Nausea 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Hairy Cell 2Blast Crisis 2Waldenstrom Macroglobulinemia 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Squamous Cell Carcinoma of Head and Neck 1Somatoform Disorders 1Smoldering Multiple Myeloma 1Sezary Syndrome 1Recurrence 1Primary Myelofibrosis 1

Interventions

Tamoxifen 10Chemotherapy, Adjuvant 7Radiotherapy 5Early Intervention, Educational 5Psychiatric Rehabilitation 4Neoadjuvant Therapy 4Letrozole 4Counseling 4Behavior Therapy 4Anastrozole 4Methods 3Mass Spectrometry 3Magnetic Resonance Spectroscopy 3Immunohistochemistry 3Gene Expression Profiling 3Biopsy 3Telemedicine 2Taxes 2Soybean Proteins 2Simvastatin 2Paclitaxel 2Medroxyprogesterone 2Fatty Acids, Omega-3 2Educational Status 2Docosahexaenoic Acids 2Curcumin 2Chromatography, High Pressure Liquid 2Brachytherapy 2telapristone acetate 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Breast Carcinoma In Situ × dexamethasone 21-phosphate × Clear all
NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

Phase 2/3 Completed
130 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡